• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

精神分裂症的早期超额死亡率。

Excess early mortality in schizophrenia.

机构信息

National Center for Register-Based Research, Aarhus University, 8210 Aarhus V, Denmark; email:

出版信息

Annu Rev Clin Psychol. 2014;10:425-48. doi: 10.1146/annurev-clinpsy-032813-153657. Epub 2013 Dec 2.

DOI:10.1146/annurev-clinpsy-032813-153657
PMID:24313570
Abstract

Schizophrenia is often referred to as one of the most severe mental disorders, primarily because of the very high mortality rates of those with the disorder. This article reviews the literature on excess early mortality in persons with schizophrenia and suggests reasons for the high mortality as well as possible ways to reduce it. Persons with schizophrenia have an exceptionally short life expectancy. High mortality is found in all age groups, resulting in a life expectancy of approximately 20 years below that of the general population. Evidence suggests that persons with schizophrenia may not have seen the same improvement in life expectancy as the general population during the past decades. Thus, the mortality gap not only persists but may actually have increased. The most urgent research agenda concerns primary candidates for modifiable risk factors contributing to this excess mortality, i.e., side effects of treatment and lifestyle factors, as well as sufficient prevention and treatment of physical comorbidity.

摘要

精神分裂症通常被认为是最严重的精神障碍之一,主要是因为患有这种疾病的人的死亡率非常高。本文回顾了有关精神分裂症患者早期过度死亡的文献,并提出了导致高死亡率的原因以及可能降低死亡率的方法。精神分裂症患者的预期寿命极短。在所有年龄组中都发现了高死亡率,导致预期寿命比普通人群短约 20 年。有证据表明,在过去几十年中,精神分裂症患者的预期寿命可能没有像普通人群那样得到同样的改善。因此,死亡率差距不仅持续存在,而且实际上可能还在扩大。最紧迫的研究议程涉及导致这种过度死亡率的可改变危险因素的主要候选因素,即治疗的副作用和生活方式因素,以及对身体合并症的充分预防和治疗。

相似文献

1
Excess early mortality in schizophrenia.精神分裂症的早期超额死亡率。
Annu Rev Clin Psychol. 2014;10:425-48. doi: 10.1146/annurev-clinpsy-032813-153657. Epub 2013 Dec 2.
2
Life expectancy and cardiovascular mortality in persons with schizophrenia.精神分裂症患者的预期寿命和心血管死亡率。
Curr Opin Psychiatry. 2012 Mar;25(2):83-8. doi: 10.1097/YCO.0b013e32835035ca.
3
[Drawing up guidelines for the attendance of physical health of patients with severe mental illness].[制定重症精神疾病患者身体健康检查指南]
Encephale. 2009 Sep;35(4):330-9. doi: 10.1016/j.encep.2008.10.014. Epub 2009 Jul 9.
4
Schizophrenia and physical health problems.精神分裂症与身体健康问题。
Acta Psychiatr Scand Suppl. 2009(438):15-21. doi: 10.1111/j.1600-0447.2008.01309.x.
5
[Excess mortality of schizophrenia].[精神分裂症的超额死亡率]
Ugeskr Laeger. 2015 Mar 23;177(13):V10140556.
6
Medical risk in patients with bipolar disorder and schizophrenia.双相情感障碍和精神分裂症患者的医疗风险。
J Clin Psychiatry. 2006;67 Suppl 9:25-30; discussion 36-42.
7
Causes of premature mortality in schizophrenia: a review of literature published in 2018.精神分裂症患者早逝的原因:对 2018 年发表的文献的综述。
Curr Opin Psychiatry. 2019 Sep;32(5):388-393. doi: 10.1097/YCO.0000000000000530.
8
Metabolic complications of schizophrenia and antipsychotic medications--an updated review.精神分裂症及抗精神病药物的代谢并发症——最新综述
East Asian Arch Psychiatry. 2013 Mar;23(1):21-8.
9
Antipsychotic-induced weight gain and metabolic abnormalities: implications for increased mortality in patients with schizophrenia.抗精神病药物所致体重增加及代谢异常:对精神分裂症患者死亡率增加的影响
J Clin Psychiatry. 2004;65 Suppl 7:4-18; quiz 19-20.
10
[Schizophrenia--a life shortening disease].[精神分裂症——一种缩短寿命的疾病]
Harefuah. 2010 Aug;149(8):508-11, 551.

引用本文的文献

1
Molecular Underpinning of Treatment-Resistant Schizophrenia: A Putative Different Neurobiology from Treatment-Responsive Schizophrenia.难治性精神分裂症的分子基础:与反应性精神分裂症不同的假定神经生物学机制
Int J Mol Sci. 2025 Sep 4;26(17):8598. doi: 10.3390/ijms26178598.
2
Nurse-led treatment engagement interventions for persons with severe mental illnesses in community settings.社区环境中针对重症精神疾病患者的护士主导的治疗参与干预措施。
World J Psychiatry. 2025 Sep 19;15(9):107720. doi: 10.5498/wjp.v15.i9.107720.
3
Semaglutide Treatment of Antipsychotic-Treated Patients With Schizophrenia, Prediabetes, and Obesity: The HISTORI Randomized Clinical Trial.
司美格鲁肽治疗精神分裂症、糖尿病前期和肥胖的抗精神病药物治疗患者:HISTORI随机临床试验
JAMA Psychiatry. 2025 Sep 3. doi: 10.1001/jamapsychiatry.2025.2332.
4
What is behind the 17-year life expectancy gap between individuals with schizophrenia and the general population?精神分裂症患者与普通人群之间17年的预期寿命差距背后的原因是什么?
Schizophrenia (Heidelb). 2025 Aug 29;11(1):117. doi: 10.1038/s41537-025-00667-1.
5
Obesity, cytokines and psychopathology in patients with chronic schizophrenia.慢性精神分裂症患者的肥胖、细胞因子与精神病理学
Front Psychiatry. 2025 Jul 28;16:1574041. doi: 10.3389/fpsyt.2025.1574041. eCollection 2025.
6
Associations of migrant and refugee status with physical comorbidity and mortality among young adults with incident non-affective psychotic disorders.初发非情感性精神障碍青年成年人中移民和难民身份与躯体共病及死亡率的关联。
BMC Public Health. 2025 Aug 6;25(1):2680. doi: 10.1186/s12889-025-24054-8.
7
Non-Linear Relationships of Loneliness with Age in People Living with Schizophrenia and Non-Psychiatric Comparison Participants: Relations non linéaires entre la solitude et l'âge chez les personnes atteintes de schizophrénie et les personnes n'ayant aucun antécédent de maladie psychiatrique.精神分裂症患者及非精神疾病对照参与者中孤独感与年龄的非线性关系:精神分裂症患者及无精神疾病史者中孤独感与年龄的非线性关系
Can J Psychiatry. 2025 Jul 28:7067437251355636. doi: 10.1177/07067437251355636.
8
Diagnosis of Schizophrenia Using Feature Extraction from EEG Signals Based on Markov Transition Fields and Deep Learning.基于马尔可夫转移场和深度学习从脑电信号中提取特征用于精神分裂症的诊断
Biomimetics (Basel). 2025 Jul 7;10(7):449. doi: 10.3390/biomimetics10070449.
9
Intrinsic metabolic and immune impairments in a genetic mouse model of schizophrenia.精神分裂症基因小鼠模型中的内在代谢和免疫损伤
Schizophrenia (Heidelb). 2025 Jul 18;11(1):100. doi: 10.1038/s41537-025-00651-9.
10
Schizophrenia management: Systematic review of current medications and Phase-3 agents (2008-2024).精神分裂症的管理:对当前药物和三期药物(2008 - 2024年)的系统评价
Neurosci Appl. 2025 Feb 6;4:105507. doi: 10.1016/j.nsa.2025.105507. eCollection 2025.